Original Article

Comparison Between Efficacy of Triamcinolone Acetonide and Bevacizumab in a Case with Type 2A Idiopathic Parafoveal Telangiectasia
  • Sabri Raza
  • Yasin Toklu
  • Mustafa Alpaslan Anayol
  • Şaban Şimşek
  • Bülent Özkan
  • Ayşegül Koçak Altıntaş
Turk J Ophthalmol 2011; 41: 6-9 DOI: 10.4274/tjo.41.02
Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy
  • Işıl Sayman Muslubaş
  • Mümin Hocaoğlu
  • Serra Arf
  • Hakan Özdemir
  • Murat Karaçorlu
Turk J Ophthalmol 2016; 46: 16-20 DOI: 10.4274/tjo.19981 PMID:27800252
Subretinal Coapplication of Tissue Plasminogen Activator and Bevacizumab with Concurrent Pneumatic Displacement for Submacular Hemorrhages Secondary to Neovascular Age-Related Macular Degeneration
  • Remzi Avcı
  • Ayşegül Mavi Yıldız
  • Esat Çınar
  • Sami Yılmaz
  • Cem Küçükerdönmez
  • Fatma Duriye Akalp
  • Emre Avcı
Turk J Ophthalmol 2021; 51: 38-44 DOI: 10.4274/tjo.galenos.2020.72540 PMID:33631914
The Effect of Intravitreal Bevacizumab on Apoptosis of Rat Retina Cells
  • Özcan Kayıkçıoğlu
  • Seda Vatansever
  • İsmet Topçu
  • Işıl Aydemir
  • Tuğçe Bilecenoğlu
  • Fatih Kahvecioğlu
  • Sinan Emre
Turk J Ophthalmol 2013; 43: 39-44 DOI: 10.4274/tjo.43.07279
Comparison between efficacy of intravitreal triamcinolone acetonide and bevacizumab on visual acuity in retinal branch vein occlusion
  • Mustafa Alpaslan Anayol
  • Yasin Toklu
  • Sabri Raza
  • Ayşe Gül Koçak Altıntaş
  • Şaban Şimşek
Turk J Ophthalmol 2009; 39: 115-120
Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion
  • Banu Aytuğ
  • Ateş Yanyalı
  • Ahmet Fazıl Nohutçu
Turk J Ophthalmol 2009; 39: 121-128
Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
  • Tuncay Topal
  • Taner Kar
  • Yıldıray Yıldırım
  • Sercan Koray Sağdıç
  • Cihan Büyükavşar
  • Abdullah Kaya
  • Ali Ayata
  • Murat Sönmez
  • Melih Hamdi Ünal
Turk J Ophthalmol 2017; 47: 133-137 DOI: 10.4274/tjo.34735 PMID:28630787
Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia
  • Ökkeş Baz
  • İhsan Yılmaz
  • Cengiz Alagöz
  • Ali Demircan
  • İrfan Perente
  • Abdullah Özkaya
  • Muhittin Taşkapılı
Turk J Ophthalmol 2017; 47: 144-148 DOI: 10.4274/tjo.04874 PMID:28630789
Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema: Early Results
  • Ceylan Uslu
  • Gökhan İbrahim Gülkılık
  • Ersin Oba
  • Banu Arslan
Turk J Ophthalmol 2010; 40: 145-150 DOI: 10.4274/tod.40.145
Survey of Intravitreal Injection Preferences for the Treatment of Age-Related Macular Degeneration and Macular Edema Among Members of the Turkish Ophthalmological Association
  • V. Levent Karabaş
  • Ecem Önder Tokuç
  • Figen Şermet
Turk J Ophthalmol 2022; 52: 179-185 DOI: 10.4274/tjo.galenos.2021.37075 PMID: 35770184
The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects
  • Cengiz Alagöz
  • Yusuf Yıldırım
  • Murat Kocamaz
  • Ökkeş Baz
  • Uğur Çiçek
  • Burcu Çelik
  • Halil İbrahim Demirkale
  • Ahmet Taylan Yazıcı
  • Muhittin Taşkapılı
Turk J Ophthalmol 2016; 46: 221-225 DOI: 10.4274/tjo.82542 PMID:28058164
Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
  • Tuğba Aydoğan
  • Gürkan Erdoğan
  • Cihan Ünlü
  • Ahmet Ergin
Turk J Ophthalmol 2016; 46: 270-273 DOI: 10.4274/tjo.23921 PMID:28050323
Application of Topical/Subconjunctival Bevacizumab and Topical Fluorometholone Acetate in Alkali Burn-induced Model of Corneal Angiogenesis
  • Ayşen Topalkara
  • Mustafa İlker Toker
  • Feyza Dursun
  • Ayşe Vural Özeç
  • Mustafa Kemal Arıcı
  • Ayhan Dursun
Turk J Ophthalmol 2010; 40: 318-322 DOI: 10.4274/tjo.40.318
Comparison of The Effect of Subkojunctival Bevacizumab and Pegaptanib Sodium in an Experimental Corneal Neovascularisation Model - Original Article
  • Volkan Hürmeriç
  • Fazıl Cüneyt Erdurman
  • Tarkan Mumcuoğlu
  • Bülent Kurt
  • Ozan Dağlı
  • Umut Karaca
  • Ali Hakan Durukan
Turk J Ophthalmol 2009; 39: 348-353
The Short-Term Effect of Intravitreal Bevacizumab Injection on Intraocular Pressure
  • Şehnaz Özçalışkan
  • Pelin Yılmazbaş
  • Faruk Öztürk
  • Özlem Beyazyıldız
Turk J Ophthalmol 2014; 44: 361-364 DOI: 10.4274/tjo.26122

Review

Use of Bevacizumab in the Treatment of Corneal Neovascularization
  • Tuba Çelik
  • Mustafa Köşker
Turk J Ophthalmol 2015; 45: 31-36 DOI: 10.4274/tjo.85530
Pharmacological Approach for Treatment of Retinopathy of Prematurity
  • İmren Akkoyun
Turk J Ophthalmol 2012; 42: 466-473 DOI: 10.4274/tjo.42.29591

Case Report

Effects of a Triple Procedure-Intravitreal Tissue Plasminogen Activator and Bevacizumab Injection Along with Pneumatic Displacement- in the Treatment of Submacular Hemorrhage Secondary to Age-Related Macular Degeneration: A Case Report
  • Yasin Toklu
  • Hasan Basri Çakmak
  • Sibel Demirel
  • Özge Saraç İlhan
Turk J Ophthalmol 2011; 41: 49-51 DOI: 10.4274/tjo.41.09
Treatment Approach to Autosomal Recessive Dystrophic Epidermolysis Bullosa
  • Rana Altan Yaycıoğlu
  • Yonca Aydın Akova
  • Fatma Selin Kaya
  • Sibel Oto
Turk J Ophthalmol 2010; 40: 107-112
Intravitreal Bevacizumab Injection Therapy in a Case with Choroidal Neovascular Membrane Secondary to Toxoplasmosis Retinochoroiditis
  • Sirel Gür Güngör
  • İmren Akkoyun
  • Evin Singar
  • Gürsel Yılmaz
Turk J Ophthalmol 2014; 44: 237-239 DOI: 10.4274/tjo.29494

Letter to Editor

Intravitreal Bevacizumab in Vitreous Hemorrhage and Diabetes Mellitus
  • Beuy Joob
  • Viroj Wiwanitkit
Turk J Ophthalmol 2017; 47: 123-124 DOI: 10.4274/tjo.91328 PMID:28405490

Original Article

Comparison of Corneal Endothelial Changes After a Single-Dose Injection of Bevacizumab or Ranibizumab
  • Fatih Horozoğlu
  • Tansu Gönen
  • Mustafa Yaşar
  • Özkan Sever
  • Kadircan Keşkinbora
Turk J Ophthalmol 2013; 43: 391-394 DOI: 10.4274/tjo.82621